Drug Type Antibody drug conjugate (ADC) |
Synonyms LY4170156, MBK 103, MBK-103 |
Target |
Mechanism FOLR1 antagonists(Folate receptor alpha antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Mablink Bioscience SASStartup |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC8H16N2O3 |
InChIKeyHSRXSKHRSXRCFC-WDSKDSINSA-N |
CAS Registry27493-61-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | US | 06 May 2024 | |
Advanced Malignant Solid Neoplasm | Phase 1 | JP | 06 May 2024 | |
Advanced Malignant Solid Neoplasm | Phase 1 | AU | 06 May 2024 | |
Colorectal Cancer | Phase 1 | US | 06 May 2024 | |
Colorectal Cancer | Phase 1 | JP | 06 May 2024 | |
Colorectal Cancer | Phase 1 | AU | 06 May 2024 | |
Endometrial Carcinoma | Phase 1 | US | 06 May 2024 | |
Endometrial Carcinoma | Phase 1 | JP | 06 May 2024 | |
Endometrial Carcinoma | Phase 1 | AU | 06 May 2024 | |
Non-Small Cell Lung Cancer | Phase 1 | US | 06 May 2024 |